The CPRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CPRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CPRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CPRX Detailed Price Forecast - CNN Money||View CPRX Detailed Summary - Google Finance|
|View CPRX Detailed Summary - Yahoo! Finance||View CPRX Stock Research & Analysis - Zacks.com|
|View CPRX Trends & Analysis - Trade-Ideas||View CPRX Major Holders - Barrons|
|View CPRX Call Transcripts - NASDAQ||View CPRX Breaking News & Analysis - Seeking Alpha|
|View CPRX Annual Report - CompanySpotlight.com||View CPRX OTC Short Report - OTCShortReport.com|
|View CPRX Fundamentals - TradeKing||View CPRX SEC Filings - Bar Chart|
|View Historical Prices for CPRX - The WSJ||View Performance/Total Return for CPRX - Morningstar|
|View the Analyst Estimates for CPRX - MarketWatch||View the Earnings History for CPRX - CNBC|
|View the CPRX Earnings - StockMarketWatch||View CPRX Buy or Sell Recommendations - MacroAxis|
|View the CPRX Bullish Patterns - American Bulls||View CPRX Short Pain Metrics - ShortPainBot.com|
|View CPRX Stock Mentions - StockTwits||View CPRX Stock Mentions - PennyStockTweets|
|View CPRX Stock Mentions - Twitter||View CPRX Investment Forum News - Investor Hub|
|View CPRX Stock Mentions - Yahoo! Message Board||View CPRX Stock Mentions - Seeking Alpha|
|View Insider Transactions for CPRX - SECform4.com||View Insider Transactions for CPRX - Insider Cow|
|View CPRX Major Holdings Summary - CNBC||View Insider Disclosure for CPRX - OTC Markets|
|View Insider Transactions for CPRX - Yahoo! Finance||View Institutional Holdings for CPRX - NASDAQ|
|View CPRX Stock Insight & Charts - FinViz.com||View CPRX Investment Charts - StockCharts.com|
|View CPRX Stock Overview & Charts - BarChart||View CPRX User Generated Charts - Trading View|
Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer
Posted on Wednesday June 13, 2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of Daniel J. Brennan as Chief Commercial Officer. Mr. Brennan will be responsible for leading the Company’s marketing, sales and commercial operations as Catalyst prepares for a potential launch of Firdapse®. “We are pleased to welcome Dan to the Catalyst team, as he brings extensive experience in leading the commercial efforts at biopharmaceutical companies, particularly those focused on orphan, neurological diseases,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals.
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
Posted on Tuesday June 12, 2018
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit Committee. Mr. Daly has supported the successful launch of 10 drugs during a 27-year career in the biotech and pharmaceutical industry. With his appointment, the Opiant Board now consists of six members, four of whom are independent.
Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Posted on Thursday May 31, 2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the Company will be presenting at the Jefferies 2018 Global Healthcare Conference, in New York. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Wednesday, June 6 at 8:00 am ET.
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced today that its New Drug Application (NDA) for Firdapse® for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) has been accepted for a Priority Review by the U.S. Food and Drug Administration (FDA). Priority Review is granted by the FDA to drugs with the potential to address a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition.